Entero Healthcare Solutions Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
ENTERO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.9 pts less than Nifty Microcap 250 and 4.1 pts less than its Retailing peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Entero Healthcare Solutions reported its Q1 FY26 results (quarter ended June 30, 2025). On a consolidated basis, revenue from operations grew to ₹14,038 million, up about 28% from ₹10,970 million in Q1 FY25, while profit after tax rose to ₹302 million from ₹205 million, a jump of roughly 47% YoY. Consolidated EPS stood at ₹6.39 vs ₹4.62 earlier. On a standalone basis, however, revenue fell to ₹794 million from ₹1,224 million (~35% YoY) and PAT dropped to ₹70 million from ₹209 million, reflecting the impact of internal restructuring and subsidiary transfers. The auditor (MS KA & Associates) issued an unmodified review conclusion on both sets of results. The Board also extended the timeline for acquiring stakes in four target pharma distribution entities (Well Wisher Pharma, Khera Medisolutions, AV Medisolutions, Anand Medical Distributors) from August 15, 2025 to November 30, 2025.
Consolidated results show strong top-line and bottom-line growth, which is the more relevant figure for investors given the group's structure, and should be viewed positively. The standalone decline and acquisition timeline extension are routine but worth monitoring for execution. No auditor qualifications were raised.